Cuban vaccine candidates, all a success of the national biotechnology.

Havana: The president of Cuba, Miguel Diaz-Canel, praised the country’s progress in immunizing the population against Covid-19 with the use of vaccine candidates produced by the national biotechnology industry, Prensa Latina publishes.

The president tweeted highlighting that, between clinical trials and controlled intervention studies, thousands of Cubans are receiving the doses of Soberana-02 and Abdala, which opens the way to mass vaccination.

‘Dreaming and continuing a country: This year we will advance in immunization with our vaccines!’, he stated.

The head of state also tweeted thanking those who created the vaccines and those who produce them, ‘because they not only inject our body,’ but also sow ‘security and hope in the national soul.’

Cuban health authorities announced yesterday that 70 percent of the Cuban population will be immunized against SARS-CoV-2 between July and August of this year, thanks to a staggered vaccination strategy, which involves different population groups between 19 and 80 years.

As part of the phase III clinical trials currently being conducted, 44,010 people will be inoculated with Soberana-02 in Havana, and 48 thousand with Abdala in the eastern part of the country.

The purpose is to gradually immunize the population, so that 1.7 million people will be protected against the virus between April and May. Later, the research will be extended to other population groups, in a larger trial with both vaccine candidates.

Redacción digital

Deja una respuesta

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *